Embera NeuroTherapeutics, Inc.

Cytokinetics’ Omecamtiv For Heart Failure Cytokinetics, Inc. is expected to release top-line data from the Phase III METEORIC-HF study of omecamtiv mecarbil, a selective cardiac myosin activator, by

Editas Patents Preserved As Gene Editing Nears Clinic The gene-editing specialist Editas Medicine Inc. is working on preclinical studies to support the filing of its first investigational new drug

Biopharma, medtech and diagnostics firms raised 51% more Series A money in the first half of 2015 than during the same period last year. According to data from Informa’s Strategic Transactions , they

IN VITRO DIAGNOSTICS Admera Health Admera Health closes Series A round Admera Health (molecular diagnostics) raised an undisclosed sum in its Series A round from lead investor Prime Value Capi